Health democracy

As a public health player, Gustave Roussy attaches great importance to health democracy. This term covers patients' rights and the desire to involve all players in the healthcare system in the development and implementation of healthcare policies. In line with one of the recommendations of the French National Authority for Health (HAS), which aims to support and encourage the involvement of patients in the world of healthcare, Gustave Roussy has been working for several years to encourage the creation of spaces and bodies for the involvement of patients and their carers.

The Lancet - A clinical trial proves the efficacy of sunitinib in the treatment of rare neuroendocrine tumors

Villejuif, 12 March 2024

The Lancet
A clinical trial proves the efficacy of sunitinib in the treatment of rare neuroendocrine tumors

Led by Dr. Éric Baudin, head of Gustave Roussy’s endocrine tumors committee, the European trial FIRSTMAPP is the first-ever randomized clinical trial concerning phaeochromocytomas and paragangliomas, rare neuroendocrine tumors. The results, published in February 2024 in The Lancet, show the efficacy of sunitinib, a tyrosine kinase inhibitor.

Medical mediator

Listening and dialogue

Concerned about the well-being of patients and the quality of care, Gustave Roussy provides its patients with areas for listening and dialogue organised around medical mediation.

Since 2017, Dr Bernard Escudier has held the position of medical mediator.

His role is to establish a dialogue with the patient or relatives by providing them with a listening ear, answers and solutions.

Pages